CD274 and non-small cell lung carcinoma: Among 305 patients with advanced NSCLC with a PD-L1 expression of at least 50%, randomized to pembrolizumab or cisplatin, overall survival at six months was 80.2% and 72.4% for the immunotherapy and chemotherapy, respectively [17].